The Billion-Dollar Peptides Gold Rush
The Billion-Dollar Peptides Gold Rush Bloomberg.com
Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Bloomberg.com.
Read the full story at Bloomberg.com
More in Pharmaceutical
Popular antidepressant recalled for high levels of a potentially cancer-causing chemical
Breckenridge Pharmaceutical has issued a recall for nearly 360,000 bottles of duloxetine, a generic version of the antidepressant Cymbalta, due to the presence of potentially carcinogenic chemicals. The U.S. Food and Drug Administration (FDA) reported that the medication contained elevated levels of nitrosamines, which may increase the risk of cancer over time. This recall underscores the pharmaceutical industry's ongoing struggle with impurity management in generic drug production and the critical role of regulatory oversight in maintaining patient safety.
June 21, 2026Times Opinion: A transparent ruse against reproductive rights
Times Opinion: A transparent ruse against reproductive rights Chattanooga Times Free Press
June 21, 2026US Launches Investigation into Drug Prices in Germany, Risking Renewed Tensions with Europe
The United States government has initiated a formal investigation into Germany's pharmaceutical pricing policies, alleging that the country’s healthcare system systematically underpays for innovative medicines. This move by the Trump administration aims to address claims that European price regulations force pharmaceutical companies to charge higher prices in the U.S. market to recoup research and development costs. For the pharmaceutical sector, this escalation signals a significant shift in trade relations that could impact global pricing strategies and market access across the European Union.
June 21, 2026FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps
The U.S. Food and Drug Administration has highlighted a recall of duloxetine, drawing attention to persistent quality gaps in generic drug manufacturing. This development serves as a reminder of the regulatory pressures facing generic producers to ensure consistency and safety in their production processes. The situation is significant for the pharmaceutical industry as it emphasizes the potential risks associated with manufacturing oversight in the generic market.
June 20, 2026